Loading clinical trials...
Loading clinical trials...
A Double-blind, Placebo Controlled, Randomized Study to Evaluate the Safety and Tolerability of INCB019602 Plus Metformin Compared to Metformin Alone in Type 2 Diabetic Subjects
Determine the effect of treatment with INCB019602 administered as an add-on to stable dose metformin therapy in type 2 diabetic subjects on safety and glycemic control.
Age
18 - 70 years
Sex
ALL
Healthy Volunteers
No
Phoenix, Arizona, United States
Tucson, Arizona, United States
Chula Vista, California, United States
Los Angeles, California, United States
Mission Viejo, California, United States
Orange, California, United States
Paramount, California, United States
San Diego, California, United States
Santa Ana, California, United States
Tustin, California, United States
Start Date
May 1, 2008
Primary Completion Date
February 1, 2009
Completion Date
June 1, 2009
Last Updated
October 30, 2012
48
ACTUAL participants
INCB019602
DRUG
INCB019602
DRUG
INCB019602
DRUG
INCB019602
DRUG
INCB019602
DRUG
Placebo
DRUG
Metformin
DRUG
Lead Sponsor
Incyte Corporation
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06671587